RecruitingPhase 2Drug trialReduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell CarcinomaThis is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.